Annual report
3055.TEDINET S100W54R
Period2024-04-01 → 2025-03-31
Filed2025-06-26
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥289.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥275.4bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥262.6bn | 2022-04-01 → 2023-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥248.4bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥239.5bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.9bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥2.8bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | ¥3.6bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥3.9bn | 2022-04-01 → 2023-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.4bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.7bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.7bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥3.5bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥2.7bn | 2022-04-01 → 2023-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.8bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.5bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥2.2bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥147.5bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥147.3bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥137.9bn | at 2023-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥136.9bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥133.0bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥85.6bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥86.6bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥61.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥60.7bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥57.4bn | at 2023-03-31d | Cons. | Net assets |
| Net assets / equity | ¥55.5bn | at 2022-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥54.4bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥17.7bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥20.8bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥17.7bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥20.8bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥18.0bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥21.1bn | at 2022-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥20.4bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | −¥262m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥828m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥1.8bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.7bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥990m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥898m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥835m | 2022-04-01 → 2023-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥849m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥731m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥116.44 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥100.2 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.41 | 2022-04-01 → 2023-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.44 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥64.01 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,942.63 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,819.99 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,614.23 | at 2023-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,460.67 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,346.36 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 41.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.2% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.6% | at 2023-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 40.9% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 4.0% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 3.7% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 2.8% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,605 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,601 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 1,626 | at 2023-03-31d | Cons. | Number of employees |
| Employees | 1,625 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 1,570 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥1.6bn | 2024-04-01 → 2025-03-31 | Standalone | Net sales |
| Revenue | ¥1.6bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥1.9bn | 2022-04-01 → 2023-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.8bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥320m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥382m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | ¥411m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥472m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥799m | 2022-04-01 → 2023-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥289m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥785m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥411m | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥337m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | ¥407m | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥334m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥1.2bn | 2022-04-01 → 2023-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥619m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥637m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥43.0bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥44.3bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥44.4bn | at 2023-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥44.5bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥44.6bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.3bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.6bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥41.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥42.9bn | at 2023-03-31d | Standalone | Net assets |
| Net assets / equity | ¥42.9bn | at 2022-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥43.1bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥2.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥2.3bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥19.19 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.39 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥52.36 | 2022-04-01 → 2023-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.27 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥27.33 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥20 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥20 | 2022-04-01 → 2023-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥15 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,984.17 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,986.27 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,955.09 | at 2023-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,900.56 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,859.64 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 97.0% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.8% | at 2023-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 96.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 1.0% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 0.8% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.7% | 2022-04-01 → 2023-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.4% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 24,400,000 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2023-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 24,400,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 59 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 58 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 63 | at 2023-03-31d | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 62 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Otherother segments | capex | 2024-04-01 → 2025-03-31 | ¥33m |
| Otherother segments | depreciation | 2024-04-01 → 2025-03-31 | ¥28m |
| Otherother segments | revenue | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Otherother segments | revenue external | 2024-04-01 → 2025-03-31 | ¥57m |
| Otherother segments | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.7bn |
| Otherother segments | segment assets | at 2025-03-31 | ¥43.2bn |
| Otherother segments | segment profit | 2024-04-01 → 2025-03-31 | ¥325m |
| Dispensing Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥102m |
| Dispensing Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥80m |
| Dispensing Industryreportable segment | employees | at 2025-03-31 | 308 pure |
| Dispensing Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥12.8bn |
| Dispensing Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥12.8bn |
| Dispensing Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥11m |
| Dispensing Industryreportable segment | segment assets | at 2025-03-31 | ¥6.1bn |
| Dispensing Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥105m |
| Information And Communication Technology Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥13m |
| Information And Communication Technology Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥26m |
| Information And Communication Technology Industryreportable segment | employees | at 2025-03-31 | 80 pure |
| Information And Communication Technology Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥2.4bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥895m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| Information And Communication Technology Industryreportable segment | segment assets | at 2025-03-31 | ¥1.0bn |
| Information And Communication Technology Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥18m |
| Medical Equipment Wholesale Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥301m |
| Medical Equipment Wholesale Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥254m |
| Medical Equipment Wholesale Industryreportable segment | employees | at 2025-03-31 | 424 pure |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥70.0bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥69.5bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥536m |
| Medical Equipment Wholesale Industryreportable segment | segment assets | at 2025-03-31 | ¥28.1bn |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Nursing Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥152m |
| Nursing Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥230m |
| Nursing Industryreportable segment | employees | at 2025-03-31 | 257 pure |
| Nursing Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Nursing Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥4.4bn |
| Nursing Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥10m |
| Nursing Industryreportable segment | segment assets | at 2025-03-31 | ¥5.6bn |
| Nursing Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥319m |
| Wholesaler Of Drugs Industryreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥2.0bn |
| Wholesaler Of Drugs Industryreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥525m |
| Wholesaler Of Drugs Industryreportable segment | employees | at 2025-03-31 | 467 pure |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥209.7bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥201.9bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥7.8bn |
| Wholesaler Of Drugs Industryreportable segment | segment assets | at 2025-03-31 | ¥99.2bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥301.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥289.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥11.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥183.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | ¥3.6bn |
| Otherother segments | capex | 2023-04-01 → 2024-03-31 | ¥48m |
| Otherother segments | depreciation | 2023-04-01 → 2024-03-31 | ¥36m |
| Otherother segments | revenue | 2023-04-01 → 2024-03-31 | ¥1.8bn |
| Otherother segments | revenue external | 2023-04-01 → 2024-03-31 | ¥57m |
| Otherother segments | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Otherother segments | segment assets | at 2024-03-31 | ¥44.5bn |
| Otherother segments | segment profit | 2023-04-01 → 2024-03-31 | ¥384m |
| Dispensing Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥144m |
| Dispensing Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥73m |
| Dispensing Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥13.3bn |
| Dispensing Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥13.3bn |
| Dispensing Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥12m |
| Dispensing Industryreportable segment | segment assets | at 2024-03-31 | ¥6.3bn |
| Dispensing Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥120m |
| Information And Communication Technology Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥11m |
| Information And Communication Technology Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥25m |
| Information And Communication Technology Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Information And Communication Technology Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥595m |
| Information And Communication Technology Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Information And Communication Technology Industryreportable segment | segment assets | at 2024-03-31 | ¥858m |
| Information And Communication Technology Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥39m |
| Medical Equipment Wholesale Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥160m |
| Medical Equipment Wholesale Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥221m |
| Medical Equipment Wholesale Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥66.5bn |
| Medical Equipment Wholesale Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥66.0bn |
| Medical Equipment Wholesale Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥527m |
| Medical Equipment Wholesale Industryreportable segment | segment assets | at 2024-03-31 | ¥27.7bn |
| Medical Equipment Wholesale Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.3bn |
| Nursing Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥177m |
| Nursing Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥223m |
| Nursing Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Nursing Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥4.3bn |
| Nursing Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8m |
| Nursing Industryreportable segment | segment assets | at 2024-03-31 | ¥5.6bn |
| Nursing Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥326m |
| Wholesaler Of Drugs Industryreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2.0bn |
| Wholesaler Of Drugs Industryreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥484m |
| Wholesaler Of Drugs Industryreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥199.5bn |
| Wholesaler Of Drugs Industryreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥191.1bn |
| Wholesaler Of Drugs Industryreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥8.4bn |
| Wholesaler Of Drugs Industryreportable segment | segment assets | at 2024-03-31 | ¥98.5bn |
| Wholesaler Of Drugs Industryreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥2.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥287.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥275.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥11.7bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥183.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥3.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,965
| Item | Context | Value | Unit |
|---|---|---|---|
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row4Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)持田製薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row5Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)ゼリア新薬工業株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row6Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)鳥居薬品株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row7Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)杏林製薬株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row8Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)協和キリン株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row9Member | Original text (Japanese)有 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)明治ホールディングス株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row10Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)武田薬品工業株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row11Member | Original text (Japanese)無 | |
| Name of securities details of specified investment equity securities held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)住友ファーマ株式会社 | |
| Purpose of shareholding overview of business alliance quantitative effects of shareholding and reason for increase in number of shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Text · Plus | |
| Whether issuer of aforementioned shares holds reporting companys shares details of specified investment shares held for purposes other than pure investment reporting company | CurrentYearInstant_Row12Member | Original text (Japanese)有 | |
| Footnotes specified investment shares held for purposes other than pure investment reporting company (text) | CurrentYearInstant_Row1Member | Text · Plus | |
| Regulations in accordance with which consolidated financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Regulations in accordance with which financial statements have been prepared financial information | CurrentYearDuration | Text · Plus | |
| Description of fact that financial statements have been prepared in accordance with special provision financial information | CurrentYearDuration | Original text (Japanese)また、当社は、特例財務諸表提出会社に該当し、財務諸表等規則第127条の規定により財務諸表を作成しております。 | |
| Note on independent audit financial information | CurrentYearDuration | Text · Plus | |
| Remarkable efforts to ensure fair presentation of consolidated financial statements etc financial information | CurrentYearDuration | Text · Plus | |
| Consolidated balance sheet (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of comprehensive income (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of changes in equity (text) | CurrentYearDuration | Text · Plus | |
| Consolidated statement of cash flows (text) | CurrentYearDuration | Text · Plus | |
| Notes significant accounting policies for preparation of consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Number of consolidated subsidiaries and names of major consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Changes in scope of consolidation (text) | CurrentYearDuration | Text · Plus | |
| Number of unconsolidated subsidiaries and associates accounted for using equity method and names of major entities accounted for using equity method (text) | CurrentYearDuration | Text · Plus | |
| Disclosure about fiscal years etc of consolidated subsidiaries (text) | CurrentYearDuration | Text · Plus | |
| Disclosure of accounting policies (text) | CurrentYearDuration | Text · Plus | |
| Significant accounting estimates consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in accounting policies na consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes new accounting standards not yet applied consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes changes in presentation consolidated financial statements (text) | CurrentYearDuration | Text · Plus | |
| Notes regarding shares and bonds etc of unconsolidated subsidiaries and associates (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding pledged assets (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding revaluation of land for business (text) | CurrentYearInstant | Text · Plus | |
| Notes regarding amount of contract liabilities (text) | CurrentYearInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |